Endothelium and the brain in CNS lupus

Lupus

Volumn 12, Issue 12, 2003, Pages 919-928

  Meroni, P L ^a   Tincani, A ^b   Sepp, N ^d   Raschi, E ^a   Testoni, C ^a   Corsini, E ^c   Cavazzana, I ^b   Pellegrini, S ^a   Salmaggi, A ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b Rheumatology and Clinical Immunology   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Autoantibodies; CNS; Endothelium; SLE; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1; ENDOTHELIAL CELL ANTIBODY; PHOSPHOLIPID ANTIBODY;

BRAIN ISCHEMIA; BRAIN MICROCIRCULATION; BRAIN VASCULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; REVIEW; SEIZURE; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; BETA 2-GLYCOPROTEIN I; BINDING SITES, ANTIBODY; CELL MEMBRANE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; GLYCOPROTEINS; HUMANS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; PROGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 0141506179     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu503oa     Document Type: Review

References (55)

1. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
2. Jennekens FGI, Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology 2002; 41: 605-618.
3. Jennekens FGI, Kater L. The central nervous system in systemic lupus erythematosus. Part 2. Pathogenic mechanisms of clinical syndromes: a literature investigation. Rheumatology 2002; 41: 619-630.
4. Cines D, Pollak E, Buck C et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-3561.
5. Tedesco F, Fischetti F, Pausa M et al. Complement-endothelial cell interaction: pathophysiological implication. Mol Immunol 1999; 36: 261-268.
6. Platt JL, Dalmasso AP, Lindman BJ et al. The role of C5a and antibody in the release of heparan sulfate from endothelial cells. Eur J Immunol 1991; 21: 2887-2890.
7. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989; 264: 9053-9060.
8. Praprotnik S, Blank M, Meroni PL, Rozman B, Eldor A, Shoenfeld Y. Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells. Arthritis Rheum 2001; 44: 1484-1494.
9. Grammer AC, Lipsky PE. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum 2002; 46: 1417-1429.
10. Hollenbaugh D, Mischel Petty N, Edwards CP et al. Expression of functional CD40 by vascular endothelial cells. J Exp Med 1995; 182: 33-40.
11. Page C, Rose M, Yacoub M, Pigott R. Antigenic heterogeneity of vascular endothelium. Am J Pathol 1992; 141: 673-683.
12. Rosenberg RD, Aird WC. Vascular-bed specific haemostasis and hypercoagulable states. N Eng J Med 1999; 340: 1555-1564.
13. Brightman MW, Reese TS. Junctions between intimately apposed membranes in the vertebrate brain. J Cell Biol 1993; 92: 648-677.
14. Janzer RC, Raff MC. Astrocytes induce blood-brain-barrier properties in endothelial cells. Nature 1987; 325: 195-196.
15. Stins MF, Gilles F, Kim KS. Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol 1997; 76: 81-90.
16. Hofman FM, Dohadwala MM, Wright AD, Hinton DR, Walker SM. Exogenous tat protein activates central nervous system derived endothelial cells. J Neuroimmunol 1994; 54: 19-28.
17. Prat A, Biernacki K, Becher B, Antel JP. B7 expression and antigen presentation by human brain endothelial cells: requirement for proinflammatory cytokine. J Neuropathol Exp Neurol 2000; 59: 129-136.
18. Nguyen VA, Fürhapter C, Sepp N. Upregulation of MHC class I molecules on human microvascular endothelial cells. Microvasc Res 2001; 62: 204-207.
19. Frigerio S, Gelati M, Ciusani E et al. Immunocompetence of human microvascular brain endothelial cells: cytokine regulation of IL-1β MCP-1, IL-10, sICAM-1 and sVCAM-1. J Neurol 1998; 245: 727-730.
20. Salmaggi A, Gelati M, Dufour A et al. Expression and modulation of interferon gamma inducible chemokines (IP-10, Mig and I-TAC) in human brain endothelium and astrocytes: possible relevance for the immune invasion of the central nervous system and the pathogenesis of multiple sclerosis. J Interf Cytokine Res 2002; 22: 631-640.
21. Blais V, Rivest S. Inhibitory action of nitric oxide on circulating tumor necrosis factor-induced NF-kappa B activity and COX-2 transcription in the endothelium of the brain capillaries. J Neuropath Exp Neurol 2001; 60: 839-905.
22. Leventhal C, Rafii S, Rafii D, Shahar A, Goldman SA. Endothelial trophic support of neuronal production and recruitment from the adult mammalian subependyma. Mol Cell Neurosci 1999; 13: 450-464.
23. Berger O, Gan X, Gujuluva C et al. CXC and CC chemokine receptors on coronary and brain endothelia. Mol Med 1999; 5: 795-805.
24. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
25. Fleck RA, Rao LVM, Rapaport SI, Varki N. localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 1990; 59: 421-437.
26. Bajaj MS, Kuppuswamy MN, Manepalli AN, Bajaj SP. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Throm Haemost 1999; 82: 1047-1052.
27. Ishii H, Salem HH, Bell CE, Laposata EA, Majerus PW. Thrombomodulin: an endothelial anticoagulant protein is absent from human brain. Blood 1986; 67: 362-365.
28. Maruyama I, Bell CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries and lymphatics and on syncytiotrophoblast of human placenta. J Cell Biol 1985; 101: 363-371.
29. Wagner SL, van Nostrund WE, Lau AL et al. Co-distribution of protease nexin-1 and protease nexin-2 in brains of non-human primates. Brain Res 1993; 626: 90-98.
30. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 427: 1309-1311.
31. Roubey RA, Hoffman M. From antiphospholipid syndrome to antibody-mediated thrombosis. Lancet 1997; 350: 1491-1493.
32. Meroni PL, Riboldi P. Pathogenic mechanisms mediating antiphospholipid syndrome. Curr Opin Rheum 2001; 13: 377-382.
33. Pierangeli SS, Gharavi AE, Harris EN. Experimental thrombosis and antiphospholipid antibodies: new insights. J Autoimmun 2000; 15: 241-247.
34. Cervera R, Piette JC, Font J et al. Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2001; 46: 1019-1027.
35. Nachman RL, Silverstein R. Hypercoagulable states. Ann Int Med 1993; 119: 819-827.
36. Hess DC, Shepard JC, Adams RJ. Increased immunoglobulin binding to cerebral endothelium in patients with aPL. Stroke 1993; 24: 994-999.
37. Kondo T, Imaizumi S, Kato I, Yoshimoto T. Isolation and culture of brain endothelial cells and establishment of in vitro blood-brain barrier model. Cell Transpl 1994; 3: S35-37.
38. Del Papa N, Guidali L, Sala A et al. Endothelial cell as target for antiphospholipid antibodies. Arthritis Rheum 1997; 40: 551-561.
39. Sheng Y, Sali A, Herzog H, Lahnstein J, Krilis SA. Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J Immunol 1996; 157: 3744-3751.
40. Del Papa N, Sheng YH, Raschi E et al. Human β2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-β2glycoprotein I antibodies. J Immunol 1998; 160: 5572-5578.
41. Harper L, Savage CO. Anti-heparin antibodies: part of the repertoire of anti-endothelial cell antibodies (AECA). Lupus 1998; 7: 68-72.
42. Song J, Park YB, Lee WK, Lee KH, Lee SK. Clinical associations of anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Rheumatol Inter 2000; 20: 1-7.
43. Liu MF, Lei HY. Anti-endothelial cell antibodies in patients with systemic lupus erythematosus. J Formosan Med Ass 1991; 90: 221-224.
44. Meroni PL, Raschi E, Testoni C, et al. Functional heterogeneity of pathogenic anti-endothelial cell antibodies. In Shoenfeld Y, Harats D, Wick G eds. Atherosclerosis and autoimmunity, Amsterdam: Elsevier, 2000: 211-220.
45. Frampton G, Moriya S, Pearson JD et al. Identification of candidate endothelial cell autoantigens in systemic lupus erythematosus using a molecular cloning strategy: a role for ribosomal P protein P0 as an endothelial cell autoantigen. Rheumatology 2000; 39: 1114-1120.
46. Teh LS, Isenberg DA. Antiribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal. Arthritis Rheum 1994; 37: 307-315.
47. Yoshio T, Masuyama JI, Minota S et al. A close temporal relationship of liver disease to antiribosomal P0 protein antibodies and central nervous system disease in patients with systemic lupus erythematosus. J Rheumatol 1998; 25: 681-688.
48. Brey RL, Abbott RD, Curb JD et al. Beta 2 glycoprotein I-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke 2001; 32: 1701-1706.
49. Zelger B, Sepp N, Schmid KW, Hunter H, Klein G, Fritsch PO. Life history of cutaneous vascular lesions in Sneddon's syndrome. Hum Pathol 1992; 23: 668-675.
50. Stockhammer G, Felber SR, Zelger B et al. Sneddon's syndrome: diagnosis by skin biopsy and MRI in 17 patients. Stroke 1993; 24: 685-690.
51. Sepp N, Zelger B, Schuler G, Romani N, Fritsch P. Sneddons' syndrome-an inflammatory disorder of small arteries followed by smooth muscle proliferation. Am J Surg Pathol 1995; 19: 448-453.
52. Caronti B, Calderaro C, Alessandri C et al. Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmun 1998; 11: 425-429.
53. Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarise brain synaptoneurosomes. Lupus 1999; 8: 127-133.
54. Hoffmann G, Schobersberger W, Rieder J et al. Human dermal microvascular endothelial cells express inducible nitric oxide synthase in vitro. J Invest Dermatol 1999; 112: 387-390.
55. Swerlick RA, Garcia-Gonzalez E, Kubota Y, Xu YL, Lawley TJ. Studies of the modulation of MHC antigen and cell adhesion molecule expression on human dermal microvascular endothelial cells. J Invest Dermatol 1991; 97: 190-196.